https://www.relivebio.com/

Mellitus is developing the GCD59 Test, an in vitro diagnostic test for diabetes detection and monitoring based on research conducted by scientific co-founders Jose A. Halperin, M.D., and Michael Chorev, Ph.D., Professors of Medicine at Brigham & Women’s Hospital and at Harvard Medical School.

Aiming to develop future China Market in Cell Therapy & Biotechnology.

At SQZ we believe that cell therapies can revolutionize the way we treat diseases. The SQZ cell therapy platform can be the foundation of a new generation of therapeutics.By enabling engineering of almost any function into any cell type, the SQZ platform overcomes fundamental barriers in the field and enables the creation of previously infeasible cell therapies. Our current focus is on creating high-impact therapies for patients in the fields of oncology, infectious disease, and auto-immunity. Ultimately, SQZ has the potential to create therapies addressing a broad range of diseases.

• Co-founding and leading Orient Life, a new Venture Capital, located at Cambridge, Massachusetts for fundraising & global investment businesses in Healthcare, Life Sciences & Biotechnology• Initiating and managing collaborations with academia, industry, VC/PE, and local government globally• Managing global teams (U.S. & China) for strategic planning and business development• Serving as Board Members/Observers for portfolio companies

As the Head of Research and the Chair of Research Steering Committee, I directly report to Chief Operating Officer (COO) of Vericel Corporation (NASDAQ: VCEL). • Receiving FDA approval of Vericel's BLA for "MACI-Matrix-Induced Autologous Chondrocyte Implantation" (December, 2016), the new generation of autologous cell therapy for joint cartilage repair• Major inventor of two patents focused on next generation allogeneic cell therapy for joint cartilage regeneration

I co-lead the Musculoskeletal Tissue Engineering Laboratory. I report to Thomas J. Gill IV, M.D. (Chief of Sports Medicine at the Massachusetts General Hospital; Professor of Orthopaedic Surgery at the Harvard Medical School; Medical Director for Red Sox and New England Patriots).

I report to Michael J. Yaremchuk, M.D. (Chief of Craniofacial Plastic Surgery, MGH & HMS), Thomas J. Gill IV, M.D. (Chief of Sports Medicine, Orthopaedic Surgery, MGH & HMS), and Mark Randolph (Lab Director).

Supervisor: Jianwei Xu, M.D. Ph.D. (Professor of Plastic and Reconstructive Surgery, and Director of Tissue Engineering Research Laboratory at the Zhongshan Hospital and Fudan University)